Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ambroxol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.97 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.41 |
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | GBA1 | P04062 | 1/20 | 0.97 |
| ▸ | CNR1 | P21554 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambroxol SCHEMBL99455 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL18702 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL7855003 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL423712 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL29380194 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL28472066 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL1648757 | 0.96 | CYP2D6 (0.94) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL11533052 | 0.92 | CYP2D6 (0.87) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| SCHEMBL24446418 | 0.90 | CYP2D6 (0.84) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| SCHEMBL22927201 | 0.90 | CYP2D6 (0.84) | CYP3A4ALOX15TSHRTDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724500-A2 | MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4630787-A1 | SYSTEMS AND METHODS FOR COMPREHENSIVE AND STANDARDIZED IMMUNE SYSTEM PHENOTYPING AND AUTOMATED CELL CLASSIFICATION | Melio Healthcare Limited (GB) | 2025-10-15 | — | — | EP | claimed |
| EP-4619024-A1 | COMPOSITIONS AND METHODS OF MAIT CELL ACTIVATION | ImmunityBio, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4543931-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2025-04-30 | — | — | EP | claimed |
| WO-2024254611-A2 | MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| EP-4419670-A1 | METHODS AND NUCLEIC ACID MOLECULES FOR AAV VECTOR SELECTION | Children's Medical Research Institute (AU) | 2024-08-28 | — | — | EP | claimed |
| EP-3538083-B1 | FORMULATIONS FOR THE TREATMENT OF OCULAR SURFACE DISEASES AND RELATED METHODS | NEUVISION DEV LLC (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2024120662-A1 | SYSTEMS AND METHODS FOR COMPREHENSIVE AND STANDARDIZED IMMUNE SYSTEM PHENOTYPING AND AUTOMATED CELL CLASSIFICATION | Melio Healthcare Limited (GB) | 2024-06-13 | — | — | WO | claimed |
| WO-2024107750-A1 | COMPOSITIONS AND METHODS OF MAIT CELL ACTIVATION | IMMUNITYBIO, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023250391-A9 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2023250391-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| WO-2023064983-A1 | METHODS AND NUCLEIC ACID MOLECULES FOR AAV VECTOR SELECTION | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2023-04-27 | — | — | WO | claimed |
| US-20190254992-A1 | COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2019-08-22 | — | — | US | claimed |
| EP-3478279-A1 | COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS | Hadasit Medical Research Services And Development (IL) | 2019-05-08 | — | — | EP | claimed |
| US-10265280-B2 | Formulations for the treatment of ocular surface diseases and related methods | NEUVISION DEVELOPMENT LLC | 2019-04-23 | — | — | US | claimed |
| US-20180133173-A1 | FORMULATIONS FOR THE TREATMENT OF OCULAR SURFACE DISEASES AND RELATED METHODS | NEUVISION DEVELOPMENT LLC | 2018-05-17 | — | — | US | claimed |
| WO-2018002937-A1 | COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2018-01-04 | — | — | WO | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-4705803-A | Method of improving resorption of injected antibacterially active substances or combinations | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1987-11-10 | — | — | US | disclosed |
| US-3993778-A | ORALLY ADMINISTERING | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190254992-A1 | COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS | SSB, PMP22, TTR | SLC6A4 4842/4885KCNH2 4669/4885HRH2 2924/4885 |
| US-10265280-B2 | Formulations for the treatment of ocular surface diseases and related methods | HRH2, NEU3, SIGLEC7 | SLC6A4 1127/4885KCNH2 1693/4885HRH2 1/4885 |
| US-20180133173-A1 | FORMULATIONS FOR THE TREATMENT OF OCULAR SURFACE DISEASES AND RELATED METHODS | HRH2, NEU3, SIGLEC7 | SLC6A4 1127/4885KCNH2 1693/4885HRH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.